vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and A10 Networks, Inc. (ATEN). Click either name above to swap in a different company.

A10 Networks, Inc. is the larger business by last-quarter revenue ($75.0M vs $44.9M, roughly 1.7× AbCellera Biologics Inc.). A10 Networks, Inc. runs the higher net margin — 16.0% vs -19.9%, a 36.0% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 13.4%). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 11.7%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

A10 Networks, Inc. is an American public company specializing in the manufacturing of application delivery controllers. Founded in 2004 by Lee Chen, co-founder of Foundry Networks, A10 originally serviced just the identity management market with its line of ID Series products. In early 2007, they added bandwidth management appliances. The company had its initial public offering on March 21, 2014, raising $187.5 million.

ABCL vs ATEN — Head-to-Head

Bigger by revenue
ATEN
ATEN
1.7× larger
ATEN
$75.0M
$44.9M
ABCL
Growing faster (revenue YoY)
ABCL
ABCL
+775.0% gap
ABCL
788.4%
13.4%
ATEN
Higher net margin
ATEN
ATEN
36.0% more per $
ATEN
16.0%
-19.9%
ABCL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
11.7%
ATEN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ABCL
ABCL
ATEN
ATEN
Revenue
$44.9M
$75.0M
Net Profit
$-8.9M
$12.0M
Gross Margin
79.6%
Operating Margin
-63.7%
17.3%
Net Margin
-19.9%
16.0%
Revenue YoY
788.4%
13.4%
Net Profit YoY
73.9%
EPS (diluted)
$-0.03
$0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
ATEN
ATEN
Q1 26
$75.0M
Q4 25
$44.9M
$80.4M
Q3 25
$9.0M
$74.7M
Q2 25
$17.1M
$69.4M
Q1 25
$4.2M
$66.1M
Q4 24
$5.0M
$74.2M
Q3 24
$6.5M
$66.7M
Q2 24
$7.3M
$60.1M
Net Profit
ABCL
ABCL
ATEN
ATEN
Q1 26
$12.0M
Q4 25
$-8.9M
$9.9M
Q3 25
$-57.1M
$12.2M
Q2 25
$-34.7M
$10.5M
Q1 25
$-45.6M
$9.5M
Q4 24
$18.3M
Q3 24
$-51.1M
$12.6M
Q2 24
$-36.9M
$9.5M
Gross Margin
ABCL
ABCL
ATEN
ATEN
Q1 26
79.6%
Q4 25
78.7%
Q3 25
80.1%
Q2 25
78.9%
Q1 25
79.7%
Q4 24
79.9%
Q3 24
80.5%
Q2 24
80.0%
Operating Margin
ABCL
ABCL
ATEN
ATEN
Q1 26
17.3%
Q4 25
-63.7%
18.7%
Q3 25
-851.8%
17.4%
Q2 25
-290.2%
14.9%
Q1 25
-1479.6%
13.3%
Q4 24
24.8%
Q3 24
-1439.4%
15.7%
Q2 24
-1276.2%
13.2%
Net Margin
ABCL
ABCL
ATEN
ATEN
Q1 26
16.0%
Q4 25
-19.9%
12.3%
Q3 25
-637.8%
16.3%
Q2 25
-203.3%
15.2%
Q1 25
-1077.2%
14.4%
Q4 24
24.7%
Q3 24
-785.4%
18.9%
Q2 24
-504.3%
15.8%
EPS (diluted)
ABCL
ABCL
ATEN
ATEN
Q1 26
$0.17
Q4 25
$-0.03
$0.13
Q3 25
$-0.19
$0.17
Q2 25
$-0.12
$0.14
Q1 25
$-0.15
$0.13
Q4 24
$0.24
Q3 24
$-0.17
$0.17
Q2 24
$-0.13
$0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
ATEN
ATEN
Cash + ST InvestmentsLiquidity on hand
$128.5M
$57.9M
Total DebtLower is stronger
$219.2M
Stockholders' EquityBook value
$966.9M
$220.8M
Total Assets
$1.4B
$634.4M
Debt / EquityLower = less leverage
0.99×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
ATEN
ATEN
Q1 26
$57.9M
Q4 25
$128.5M
$684.6M
Q3 25
$83.2M
$370.9M
Q2 25
$92.4M
$367.4M
Q1 25
$159.3M
$355.8M
Q4 24
$156.3M
$195.6M
Q3 24
$126.6M
$182.1M
Q2 24
$148.3M
$177.1M
Total Debt
ABCL
ABCL
ATEN
ATEN
Q1 26
$219.2M
Q4 25
$218.8M
Q3 25
$218.4M
Q2 25
$218.1M
Q1 25
$217.7M
Q4 24
$0
Q3 24
Q2 24
Stockholders' Equity
ABCL
ABCL
ATEN
ATEN
Q1 26
$220.8M
Q4 25
$966.9M
$211.5M
Q3 25
$964.0M
$206.2M
Q2 25
$1.0B
$204.0M
Q1 25
$1.0B
$195.9M
Q4 24
$1.1B
$231.8M
Q3 24
$1.1B
$217.3M
Q2 24
$1.1B
$214.4M
Total Assets
ABCL
ABCL
ATEN
ATEN
Q1 26
$634.4M
Q4 25
$1.4B
$629.8M
Q3 25
$1.4B
$620.1M
Q2 25
$1.4B
$607.9M
Q1 25
$1.3B
$606.2M
Q4 24
$1.4B
$432.8M
Q3 24
$1.4B
$407.7M
Q2 24
$1.4B
$397.2M
Debt / Equity
ABCL
ABCL
ATEN
ATEN
Q1 26
0.99×
Q4 25
1.03×
Q3 25
1.06×
Q2 25
1.07×
Q1 25
1.11×
Q4 24
0.00×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
ATEN
ATEN
Operating Cash FlowLast quarter
$-34.7M
$2.2M
Free Cash FlowOCF − Capex
$-44.6M
FCF MarginFCF / Revenue
-99.4%
Capex IntensityCapex / Revenue
21.9%
3.9%
Cash ConversionOCF / Net Profit
0.19×
TTM Free Cash FlowTrailing 4 quarters
$-174.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
ATEN
ATEN
Q1 26
$2.2M
Q4 25
$-34.7M
$22.7M
Q3 25
$-52.6M
$22.8M
Q2 25
$-32.4M
$22.2M
Q1 25
$-11.6M
$17.2M
Q4 24
$-108.6M
$25.7M
Q3 24
$-28.9M
$20.1M
Q2 24
$-30.0M
$12.2M
Free Cash Flow
ABCL
ABCL
ATEN
ATEN
Q1 26
Q4 25
$-44.6M
$16.0M
Q3 25
$-61.5M
$18.1M
Q2 25
$-45.8M
$17.9M
Q1 25
$-22.2M
$12.7M
Q4 24
$-187.0M
$23.3M
Q3 24
$-47.4M
$16.7M
Q2 24
$-50.1M
$8.7M
FCF Margin
ABCL
ABCL
ATEN
ATEN
Q1 26
Q4 25
-99.4%
20.0%
Q3 25
-687.0%
24.2%
Q2 25
-267.9%
25.9%
Q1 25
-524.0%
19.2%
Q4 24
-3702.8%
31.4%
Q3 24
-728.4%
25.0%
Q2 24
-683.8%
14.5%
Capex Intensity
ABCL
ABCL
ATEN
ATEN
Q1 26
3.9%
Q4 25
21.9%
8.3%
Q3 25
99.7%
6.3%
Q2 25
78.2%
6.1%
Q1 25
251.1%
6.8%
Q4 24
1552.7%
3.2%
Q3 24
284.6%
5.2%
Q2 24
274.6%
5.8%
Cash Conversion
ABCL
ABCL
ATEN
ATEN
Q1 26
0.19×
Q4 25
2.30×
Q3 25
1.87×
Q2 25
2.10×
Q1 25
1.80×
Q4 24
1.40×
Q3 24
1.59×
Q2 24
1.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABCL
ABCL

Segment breakdown not available.

ATEN
ATEN

Products$44.0M59%
Services$31.0M41%

Related Comparisons